ACTERO LAUNCHES CAPECITABINE ACTE 500MG

December 20, 2017

Author: Acteropharma

Actero Middle East is pleased to announce the launch of its first product to the Iranian market. This launch is a milestone for our young company, but it is only the first step towards building our oncology portfolio. Capecitabine ACTe 500 mg tablets are equivalent to Xeloda tablets, a chemotherapy medication used to treat breast cancer, gastric cancer and colorectal cancer. “The approval and launch of Capecitabine ACTe is good news for oncologists and patients that will have access to a wider range of quality products to choose from. We aim to make our products available in the market and hope to create more competition based solely on quality and let doctors make their choice.” Dr. Tiam Esfahani, Sales and Marketing Director Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

Last News

Actero Support in Congress 1400

Site
July 24, 2022

Author:

Acteropharma
Actero company’s social respomsibility of patient support in Hematology-Oncology Congress and Radiation Therapy Congress

Best of ASCO 2021

Dr-noroozi-event-2048x1367
November 16, 2021

Author:

Acteropharma
The aforesaid seminar has been held for the first time in Iran with the hospitality of Isfahan city, with the cooperation of Radiation-Oncologists from all over of the country and Actero Pharma.

“Uro-Oncology Tumor board: Challenges of Prostate Cancer Treatment” (Semi-Virtual)

Dr-noroozi-event-2048x1367
November 16, 2021

Author:

Acteropharma
Uro-Oncology research Center of Tehran University of Medical science, in cooperation with Actero Pharma has held a semi-virtual tumor board.